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ABSTRACT
Introduction: Resistance to macrolides, lincosamides and streptogramins B (MLSB antibiot-
ics) in staphylococci may be due to modification in ribosomal target methylase encoded by 
erm genes. The expression of MLSB resistance lead to three phenotypes, namely constitutive 
resistance (cMLSB), inducible resistance (iMLSB), and resistance only to macrolides and strep-
togramins B (MSB). The iMLSB resistance is the most difficult to detect in the clinical labora-
tory. Objective: This study investigated the expression of MLSB resistance and the prevalence 
of the erm genes among 152 clinical isolates of Staphylococcus aureus and coagulase-negative 
Staphylococcus (CNS) from Hospital de Clínicas de Porto Alegre. Methods: Primary MLSB resist-
ance was detected by the disk diffusion method. Isolates with iMLSB phenotype were tested by 
double-disk induction method. All isolates were tested by a genotypic assay, PCR with specific 
primers. Results: A total of 46.7% of staphylococci were positive for cMLSB; 3.3% for iMLSB and 
3.3% for MSB. One or more erm genes were present in 50.1% of isolates. The gene ermA was 
detected in 49 isolates, ermC in 29 and ermB in 3. Conclusion: The prevalence of the ermA, 
ermB and ermC genes were 29.6%, 17.1% and 0.66% respectively, and constitutive resistance 
was the most frequent as compared to the other two phenotypes. 
Keywords: Staphylococcus; resistance; erm genes; macrolides.
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INTRODUCTION
Staphylococcus aureus and coagulase nega-
tive staphylococci (CNS) are recognized to 
be causing nosocomial and community-
acquired infections worldwide. A great con-
cern related to these microorganisms is their 
ability to develop resistance to antibiotics 
which originally were active against these 
species.1,2,3 Although β-lactam antibiotics 
are the main compounds used to treat infec-
tions due to staphylococci, macrolides, lin-
cosamides e streptogramins type B (MLSB) 
antibiotics are also widely used to treat sta-
phylococcal infections. These antibiotics 
exert similar inhibitory effects on bacterial 
protein synthesis, but they are chemically 
distinct.4,5 MLSB resistance can be caused by 
several mechanisms, but the predominant 
form is target modification mediated by 
ermA, ermB e ermC (erythromycin ribosome 
methylase) genes.4,5 The erm genes encode 
enzymes that confer inducible or constitutive 
resistance to MLSB agents via methylation of 
the 23S rRNA, thereby reducing binding by 
MLSB agents to the ribosome.
6,7 Constitutive 
MLSB resistance can be detected by the disk 
diffusion test in laboratorial routine.8 Strains 
with constitutive MLSB resistance show 
high-level in vitro cross resistance among 
MLSB drugs. However, staphylococci isolates 
with inducible MLSB resistance demonstrate 
clear in vitro resistance to 14 and 15-member
macrolides (e.g., erythromycin), while they
seem to be susceptible to 16-member mac-
rolides, lincosamides and streptogramins 
type B. Therefore, strains can show in vitro 
erythromycin resistance and false clindamy-
cin susceptibility, because the conventional 
disk-diffusion may fail to detect inducible 
MLSB resistance.
4,9,10 The Clinical and Labo-
ratory Standards Institute (CLSI) developed 
a phenotypic method (the double-disk dif-
fusion test (D test) to screen for inducible 
resistance.11 However, the polymerase chain 
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reaction (PCR) with specific primers is a genotypic 
method used to confirm the presence of the MLSB genes, 
ermA, ermB e ermC.12 The risk for therapeutic failure 
is increased as constitutive resistance may raise from 
iMLSB during the course of clindamycin therapy in pa-
tients with severe staphylococci infections.11
The objective of this study was to determine the prev-
alence of the MLSB genes in Staphylococcus aureus and 
coagulase negative staphylococci from patients attending 
the Hospital de Clínicas de Porto Alegre (HCPA).
MATERIALS AND METHODS
Bacterial isolates 
Isolates of S. aureus and of CNS were collected from 
consecutive clinical specimens sent to the of microbiol-
ogy laboratory of the HCPA. The period of the study 
was between September and October 2007. The bacterial 
identification was performed through Gram’s technique 
and catalase and coagulase tests. Isolates were stored in 
glycerol broth at -20°C until use. 
Susceptibility tests
The antimicrobial susceptibility test was performed by 
the disk diffusion method on Mueller Hinton Agar (bi-
oMérieux, Marcy L’Etoile, France), according to the 
Clinical and Laboratory Standards Institute (CLSI 2008), 
with the following antibiotic (Oxoid®): oxacillin (1 µg), 
cefoxitin (30 µg), vancomycin (30 µg), gentamicin (10 µg), 
clindamycin (2 µg), chloramphenicol (30 µg), doxycy-
cline (30 µg), erythromycin (15 µg), levofloxacin (5 µg), 
rifampin (5 µg) and trimethoprim-sulfamethoxazole (25 µg). 
S. aureus ATCC 25923 was used for quality control. 
The standard CLSI double-disk diffusion (D test) test 
was performed using Mueller Hinton agar (bioMérieux, 
Marcy L’Etoile, France) with a 15 µg erythromycin disk 
and 2 µg clindamycin disk (Oxoid®) placed at distances 
of 15 and 26 mm and incubated for 24 h at 35°C.11 
The inducible phenotype was characterized by a positive D test, 
a ﬂ attening of the inhibition zone around the clindamycin disk 
near to the erythromycin disk and indicates that erythromycin 
has induced clindamycin resistance (iMLSB). The phenotype 
cMLSB was characterized by erythromycin and clindamycin 
resistance. Finally, the phenotype (MSB) was characterized by 
clindamycin susceptibility and erythromycin resistance, with 
negative D test.
ermA, ermB and ermC gene detection
A direct colony suspension of the culture equivalent to a 
1.0 McFarland standard was prepared in 500 µL of 10 mM 
Tris-1 mM EDTA (pH 8.0), vortexed, and boiled for 10 min 
an aliquot of 5 µL of the suspension was used for each 25 µlL 
reaction mixture.13 
PCR assays and primers specifi c from the ermA, ermB 
and ermC resistance genes used in this study have been 
previously described by Gerard, Lina et al. (Table 1).14
Each reaction was carried out in a fi nal volume of 
25 µL and included 10 x PCR buffer (pht®); 3 mM of Mg-
Cl2 (pht®); 5 µM of each ermA, ermB and ermC forward 
and reverse primers (Invitrogen®); RNAse and DNAse free 
water; 1.25 U of Taq DNA polymerase (pht®); 2.5 mM of 
each dATP, dTTP, dCTP, and dGTP (ABgene®); and 5 µL 
of DNA. The PCR mixture was subjected to thermal cy-
cle (30 cycles of 30 s at 94°C as the denaturation step, 
30 s at 57°C as the annealing step, and of 5 min at 72°C 
as the extension step) with a JMR® PTC-100. The PCR-
amplifi ed reaction mixture was resolved by electro-
phoresis through a 2% agarose gel containing ethid-
ium bromide in Tris-borate-EDTA buffer at 12 V/cm for 
30 min. The gel was visualized under UV light and the sizes 
of the amplifi cation products were estimated by comparison 
with 100 bp molecular size standard ladder. 
Three clinical samples with positives results for each of 
the three genes were submitted to sequencing and analyzed 
by BLAST and Chromas and DDBJ/EMBL/ GenBank. These 
isolates were used as positive control in all experiments.
Table 1. Correlation between erm genes and MLSB resistance phenotypes
      Genotype
Isolate Phenotype ermA ermB ermC ermA/  ermA/  ermA/ermB/ 
     ermC ermB ermC
 40 (cMLSB) 36 1 3 0 0 0
S. aureus 3 (iMLSB) 2 0 1 0 0 0
 2 (MSB) 0 0 0 0 0 0
 24 (cMLSB) 0 0 20 2 1 1
CNS 2 (iMLSB) 0 0 2 0 0 0
 3 (MSB) 0 0 0 0 0 0
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RESULTS
A total of 152 strains including 94 S. aureus and 58 CNS were 
included in this study. Eighty-one (53.3%) exhibited eryth-
romycin resistance and were considered for evaluation of the 
three distinct MLSB resistance phenotypes (cMLSB, iMLSB, 
MSB). Among these 81 erythromycin-resistant strains, 10 
showed clindamycin susceptibly and were tested by double-
disk diffusion method. We found only fi ve (6.2%) isolates with 
iMLSB resistance phenotype (three S. aureus and two CNS) and 
fi ve (6.2%) with MSB resistance phenotype (two S. aureus and 
three CNS). The remaining 71 (87.7%) isolates were considered 
as cMLSB resistance phenotype (46 S. aureus and 25 CNS). 
All the 152 strains were tested for the presence of MLSB 
resistance genes and 77 (50.1%) contained one or more erm 
genes (Figure 1). The ermA gene was detected in 44 isolates 
(41 S. aureus and three CNS), the ermB gene was found in 
only one isolate of S. aureus and the ermC gene was detected in 
28 isolates (four S. aureus and 24 CNS). Combination of erm 
genes was detected in 4 CNS isolates (Graphics 1 and 2). For S. 
aureus isolates with cMLSB resistance phenotype, 36 presented 
the ermA gene, only one exhibited the ermB gene and three had 
the ermC gene. Moreover, in three of the S. aureus isolates with 
iMLSB resistance phenotype, two isolates were ermA positive and 
one was ermC positive. The ermC gene was identifi ed in 20 iso-
lates of CNS with cMLSB resistance phenotype and in two isolates 
of CNS with iMLSB resistance phenotype. Seven (six S. aureus and 
one CNS) isolates with cMLSB resistance phenotype did not 
present any of the three erm genes (Table 1). Resistance to non-
MLSB antibiotics in S. aureus and CNS isolates with erm genes
was higher in relation to the isolates without the erm 
genes: chloramphenicol (p = 0.004), doxycycline (p < 0.001), 
gentamicin (p < 0.001), levoﬂ oxacin (p < 0.001), oxacillin 
(p < 0.001), rifampin (p < 0.001) and, trimethoprim-sulfameth-
oxazole (p < 0.001). Of the 77 isolates who harbored erm genes, 
65 (40 S. aureus and 25 CNS) were multidrug resistant (resistant 
to fi ve or more antimicrobial class). The overall range of multire-
sistance among the staphylococci strains studied was 48.2%.
DISCUSSION
The incidence of constitutive and inducible MLSB resistance 
may vary according to different geographic region and even 
from hospital to hospital or patient group. This variability is 
usually associated with the inconsistent use of erythromycin 
in different institutions; the origin of the isolate (nosoco-
mial versus community acquired); patient age and clinical 
samples.15,16 In our study 53.3% of staphylococci presented 
one of three MLSB resistance phenotypes. In fact, cMLSB 
resistance phenotype was the most common (46.7%) and 
iMLSB and MSB phenotype were each detected in only 3.3% 
of the staphylococci.
In a study conduced in Texas by Fiebelkorn et al. the 
cMLSB resistance phenotype was also the most prevalent 
phenotype (41.7% of staphylococci) but the iMLSB was found 
in 25.2% of the isolates, indicating a difference in relation to 
iMLSB data of the present study.
10 In Europe where the MLSB 
phenotype prevalence are somehow variable, in London 
Hamilton-Miller et al. detected staphylococci with iMLSB as 
the predominant phenotype (43% of isolates) and the cMLSB 
resistance phenotype was detected in only 24% of isolates.17 
The D test is critical, in this scenario, to avoid therapeutic 
failure. On the other hand, CNS isolates studied in Sevilla 
demonstrated that the MSB resistance phenotype was more 
common (11.2%) in relation to the other phenotypes (iMLSB 
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Graphic 1: Frequency of erm genes in S. aureus isolates.
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Figure 1: (A) Lanes 1 and 2 ermA positive in 421 bp; lane 3 negative 
control; lane 4 positive control; and lane 5 100 bp molecular size 
ladder. (B) Lane 1 ermB positive in 359 bp; lane 2 negative control; 
lane 3 positive control; and lane 4 100 bp molecular size ladder. 
(C) Lane 1 ermC positive in 572 bp; lane 2 negative control; lane 
3 positive control; and lane 4 100 bp molecular size ladder. 
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7.4% and cMLSB 3.2%).
16 In contrast, the cMLSB resistance 
phenotype was most frequent (46.9%) as compared to 
iMLSB (30.2%) in France.
14
In Turkey it was demonstrated that the prevalence of the 
cMLSB phenotype is higher than that of the iMLSB phenotype 
and the MSB phenotype is low, data similar to our study.
15,18-20
A previous study conducted in our city evaluated 200 
CNS and showed that only 2.5% of isolates presented the 
iMLSB resistance phenotype.
21 Therefore, one could specu-
late that the prevalence of the inducible phenotype is low 
in our city. 
Despite the fact that there is geographic variability among 
MLSB resistance phenotypes, the prevalence of erm genes has 
been reported to be similar in various countries. According to 
our fi ndings, the ermA gene was the most prevalent among 
the S. aureus isolates (43.6%) and the ermC gene was the most 
prevalent among the SCN isolates (37.9%). Only three isolates 
of staphylococci presented the ermB gene (2.0%). The presence 
of more than one erm gene was not detected in S. aureus but it 
was observed in four SCN isolates. According to Martineau et 
al., in Canada, 20.9% of the S. aureus were positive for the ermA 
gene and 66% of CNS were positive for the ermC gene, dem-
onstrating that the prevalence of the ermA gene in S. aureus is 
slightly lower in comparison to other studies.22 A multicenter 
study in 24 European university hospitals confi rmed the high 
prevalence of ermA gene and the low prevalence of ermC and 
ermB genes among 851 S. aureus.23 Lina et al. found 63.2% of S. 
aureus with ermA gene positive and 44% of CNS strains ermC 
gene positive, while the ermB gene was present in only 1% of 
staphylococci.14 The results reported by Westh et al. in Denmark, 
also showed a high prevalence of the ermA gene in S. aureus 
isolates and the ermC gene in CNS strains, as well as a low 
prevalence for the ermB gene.24 In our study, the ermB gene was 
also detected in a small percentage of staphylococci isolates. This 
gene is generally found in animal staphylococci strains.6,14,17 
In the present study, eight isolates (three S. aureus and fi ve 
SCN) susceptible to erythromycin proved to carry erm genes 
(seven ermA e one ermC). The presence of erm genes among 
isolates of staphylococci susceptible to erythromycin had al-
ready been demonstrated in another study.22 This may be 
due to the lack of expression of erm genes due to factors 
which down regulate the expression of this gene.22,23
In our study we found six S. aureus isolates and one 
CNS resistant to erythromycin and clindamycin but with 
negative genotypic test. These results were probably asso-
ciated with the presence of other genes, such as msrA and 
msrB, with low frequency in Staphylococci species isolated 
form humans,25 which were not evaluated in this study.
We detected three S. aureus resistant to clindamycin and 
susceptible to erythromycin, which did not harbor erm genes. 
In a study conducted by Lina and et al., the only SCN sam-
ple that presented this susceptibility profi le was positive for 
the genes linA and linA´.14 These genes confer lincosamides 
resistance only in S. heamolyticus and S. aureus. Incidence of 
staphylococci with lincosamide resistance but without resist-
ance to macrolides and streptogramins is usually very low.14,26
CONCLUSION
The aim of this study was to determine the prevalence of 
the MLSB phenotypes and genes in Staphylococcus aureus 
and coagulase-negative staphylococci from patients receiv-
ing care at our hospital. We found that constitutive MLSB 
resistance was the most prevalent phenotype in staphyloco-
cci; ermA was the most prevalent gene in S. aureus strains, 
whereas ermC was the most frequent gene in CNS isolates. 
Therefore, staphylococci with resistance to MLSB are usu-
ally detected directly in routine susceptibility test and the 
“D test” is not required to be performed in most of our 
isolates. However, other regions in our country may not 
present the same resistance profi le as ours and, therefore, 
surveillance studies are warranted in different institutions. 
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